Skip to content

Clinical trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Sweden

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Country / region: Sweden Clear all

41 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20053
20072
20081
20095
20121
20133
20152
20175
20183
20194
20202
20221
20233
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed18
Recruiting11
Unknown status6
Terminated3
Active, not recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals4
Princess Maxima Center for Pediatric Oncology4
Rigshospitalet, Denmark3
Amgen2
Bristol-Myers Squibb2
Gilead Sciences2
Mats Heyman2
Nordic Society for Pediatric Hematology and Oncology2
Pfizer2
St. Anna Kinderkrebsforschung2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma41
Leukemia9
Leukemia, Myeloid, Acute7
Recurrence6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma5
Burkitt Lymphoma4
Leukemia, Lymphocytic, Chronic, B-Cell4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive4
Lymphoma, Non-Hodgkin4
Neoplasms4

Trials

Showing 76 to 41 of 41. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.